WALTHAM, Mass., Aug. 10, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced that Bristol Myers Squibb ("BMS") has licensed its fourth TriNKET™ ...

Bristol Myers Squibb (BMS) has inked a deal with Dragonfly Therapeutic for an exclusive license to its interleukin-12 immunotherapy programme. BMS will pay Dragonfly $245m upfront, with the further ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dragonfly Therapeutics Inc, announced that Bristol Myers Squibb has licensed its fourth TriNKET immunotherapy drug candidate from Dragonfly, a clinical-stage biopharmaceutical company. Since the ...

Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's ...

Bristol Myers Squibb will pay $475 million to license an experimental cytokine drug from Dragonfly Therapeutics. The therapy, called DF6002, is an IL-12 immunoglobulin Fc fusion protein. IL-12 helps ...

Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program. This program is the early-stage ...

Dragonfly to receive a $12 million payment and is eligible to receive potential future milestones and royalties on net sales. WALTHAM, Massachusetts, Aug. 10, 2020 /PRNewswire/ -- Dragonfly ...